SCHEMBL6799668

SCHEMBL6799668

Cc1cccc(N(C(=O)OC(C)(C)C)[C@@H](C)C(=O)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B1 P14061 5/20 0.38
HSD17B2 P37059 5/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
SLC7A5 Q01650 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
JAK2 O60674 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
PAX8 Q06710 1/20 0.36
ABCB1 P08183 1/20 0.36
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9382586 0.86 SMN1; SMN2 (0.41) CYP3A4CYP2C9CYP2C19TDP1SLC7A5
SCHEMBL642839 0.86 SMN1; SMN2 (0.41) CYP3A4CYP2C9CYP2C19TDP1SLC7A5
SCHEMBL28276942 0.85 CTSB (0.37) KDM4ESLC7A5MEN1KMT2ANPC1
SCHEMBL5229823 0.85 CTSB (0.37) KDM4ESLC7A5MEN1KMT2ANPC1
SCHEMBL6207126 0.85 HDAC1 (0.39) SLC7A5MEN1KMT2AALDH1A1
SCHEMBL8758891 0.82 ALDH1A1 (0.42) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL7720053 0.82 ALDH1A1 (0.42) KDM4EMAPTMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL5277142 0.81 SLC7A5 (0.39) SLC7A5
SCHEMBL1325515 0.80 MEN1 (0.43) KDM4EMAPTTDP1MEN1KMT2A
SCHEMBL995191 0.80 MEN1 (0.43) KDM4EMAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812237-B2 (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES NOVARTIS AG (CH) 2004-11-02 US disclosed
US-20030158256-A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors NOVARTIS AG (CH) 2003-08-21 US disclosed
EP-1283825-A1 N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS Novartis AG (CH) 2003-02-19 EP disclosed
WO-2001087828-A1 N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS NOVARTIS AG (CH) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158256-A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors CTSS, CTSV, CTSF CYP3A4 1011/4885CYP2C9 896/4885CYP2C19 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.